Skip to main content
LQDA
NASDAQ Life Sciences

FDA Fast Track for YUTREPIA in SSc-Raynaud's; Phase 2a RE-WARM Study to Start Q4

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$70.2
Mkt Cap
$6.237B
52W Low
$21.145
52W High
$93.61
52W Position info
232% above low
Off High info
25% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

LQDA has more than doubled off its 52-week low of $21.145.

Summary

Liquidia announced FDA Fast Track designation for YUTREPIA in SSc-Raynaud's, a condition with no approved therapy, and plans to start the RE-WARM Phase 2a study in Q4 2026.


Key Events · Product Development and Regulatory · LQDA

  • FDA Fast Track for SSc-RP

    FDA granted Fast Track designation to YUTREPIA for Raynaud's phenomenon associated with systemic sclerosis, a condition with no approved therapy affecting up to 90% of SSc patients.

  • RE-WARM Phase 2a Study

    Liquidia plans to initiate RE-WARM (NCT07748000), a ~75-patient dose-finding study at up to 30 U.S. sites, in October 2026 with primary completion targeted for February 2027.

  • Addressable Market

    Liquidia estimates ~30,000 U.S. patients with moderate to severe SSc-RP, representing a meaningful expansion opportunity beyond YUTREPIA's approved PAH and PH-ILD indications.

  • Regulatory Benefits

    Fast Track enables more frequent FDA interactions, potential rolling NDA review, and possible Priority Review or Accelerated Approval if criteria are met.


Analysis · LQDA · Life Sciences

The FDA's Fast Track designation for YUTREPIA in systemic sclerosis-associated Raynaud's phenomenon (SSc-RP) validates a new indication with no approved therapy and a ~30,000-patient U.S. opportunity. The designation enables more frequent FDA interactions, rolling NDA review, and potential Priority Review or Accelerated Approval. Liquidia plans to initiate the RE-WARM Phase 2a dose-finding study in October 2026 with primary completion targeted for February 2027. This expands YUTREPIA's commercial runway beyond its approved PAH and PH-ILD indications, though the indication remains unapproved and clinical success is not guaranteed.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, LQDA was trading at $70.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.2B. The 52-week trading range was $21.15 to $93.61. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

LQDA - Latest Insights

LQDA
Nov 10, 2026, 7:00 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $47.45
Real-time Price: $57.45 info
Change: +$10.00 (+21%) info
Market Cap: $5.177B info
LQDA
Nov 10, 2026, 6:45 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $47.40
Real-time Price: $57.45 info
Change: +$10.05 (+21%) info
Market Cap: $5.177B info
LQDA
Nov 10, 2026, 6:30 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $50.00
Real-time Price: $57.45 info
Change: +$7.45 (+15%) info
Market Cap: $5.177B info
LQDA
Oct 13, 2026, 9:49 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $39.50
Real-time Price: $57.45 info
Change: +$17.95 (+45%) info
Market Cap: $5.177B info
LQDA
Oct 13, 2026, 5:50 PM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $31.76
Real-time Price: $57.45 info
Change: +$25.69 (+81%) info
Market Cap: $5.177B info